Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JASON B FLEMING and PAUL J CHIAO.
JASON B FLEMING
Connection Strength
1.373
PAUL J CHIAO
  1. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Nat Commun. 2024 Apr 11; 15(1):3149.
    View in: PubMed
    Score: 0.246
  2. Transforming Growth Factor-? Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Clin Cancer Res. 2016 Oct 01; 22(19):4934-4946.
    View in: PubMed
    Score: 0.142
  3. Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis. PLoS One. 2014; 9(7):e101452.
    View in: PubMed
    Score: 0.125
  4. Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin Cancer Res. 2013 Feb 01; 19(3):549-59.
    View in: PubMed
    Score: 0.113
  5. KrasG12D-induced IKK2/?/NF-?B activation by IL-1a and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012 Jan 17; 21(1):105-20.
    View in: PubMed
    Score: 0.105
  6. Defective feedback regulation of NF-kappaB underlies Sjogren's syndrome in mice with mutated kappaB enhancers of the IkappaBalpha promoter. Proc Natl Acad Sci U S A. 2010 Aug 24; 107(34):15193-8.
    View in: PubMed
    Score: 0.095
  7. TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation. Cancer Res. 2009 Oct 01; 69(19):7851-9.
    View in: PubMed
    Score: 0.090
  8. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008 Apr; 7(4):829-40.
    View in: PubMed
    Score: 0.081
  9. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. J Clin Invest. 2022 12 15; 132(24).
    View in: PubMed
    Score: 0.056
  10. CES2 sustains HNF4a expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Mol Metab. 2022 02; 56:101426.
    View in: PubMed
    Score: 0.053
  11. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. JCO Precis Oncol. 2020 Nov; 4:426-436.
    View in: PubMed
    Score: 0.048
  12. Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle. Ann N Y Acad Sci. 1999 Jun 30; 880:31-7.
    View in: PubMed
    Score: 0.044
  13. Overexpression of the tumor suppressor gene Smad4/DPC4 induces p21waf1 expression and growth inhibition in human carcinoma cells. Cancer Res. 1998 Dec 15; 58(24):5656-61.
    View in: PubMed
    Score: 0.043
  14. IGFBP2 Activates the NF-?B Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2016 11 15; 76(22):6543-6554.
    View in: PubMed
    Score: 0.036
  15. IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-?B Activation. Clin Cancer Res. 2016 Mar 15; 22(6):1432-44.
    View in: PubMed
    Score: 0.034
  16. SMAD4 regulates cell motility through transcription of N-cadherin in human pancreatic ductal epithelium. PLoS One. 2014; 9(9):e107948.
    View in: PubMed
    Score: 0.032
  17. Study human pancreatic cancer in mice: how close are they? Biochim Biophys Acta. 2013 Jan; 1835(1):110-8.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.